Tag: 贵族宝贝FZP


first_img Tags drug pricingfinancegeneticsinfectious diseaselegalpharmaceuticalspharmalittlerare diseasesSTAT+ Pharmalittle: Pfizer pays $636 million for rights to gene therapies; Novartis denies bribing Greek officials Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Log In | Learn More [email protected] Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED What is it? Alex Hogan/STAT What’s included?center_img Ed Silverman Pharmalot GET STARTED About the Author Reprints Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with almond toffee for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …Pfizer (PFE) has agreed to pay up to $636 million for the rights to gene therapies under development at Vivet Therapeutics, The Wall Street Journal says. Gene therapies, which introduce new DNA into the body to address diseases caused by a single faulty gene, are attracting attention for their ability to cure intractable diseases. In the past month, both Roche (RHHBY) and Biogen (BIIB) have made bets on gene therapy. Vivet’s most advanced program is a gene therapy for Wilson disease, a rare, inherited liver disorder that causes the buildup of copper in the body. By Ed Silverman March 20, 2019 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @Pharmalot last_img read more